Sustained-release bimatoprost implant shows safety, efficacy in early study
Click Here to Manage Email Alerts
BOSTON — A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting.
Gregory J. Katz, MD, ABO, and co-authors presented 12-month interim safety and efficacy data from a first-in-human study in which 23 eyes were implanted with the SpyGlass Pharma IOL-based drug delivery platform with bimatoprost, at doses of 75 µg, 150 µg or 300 µg, at the time of cataract surgery.
A statistically significant IOP reduction was achieved in all cohorts at all timepoints. Mean IOP decreased from 25.1 mm Hg at baseline to 13.9 mm Hg at 12 months. No additional IOP-lowering medication was required. All eyes achieved best corrected visual acuity of 20/40 or better, with minimal adverse events that were unrelated to the drug delivery device.
This method of administering medication has the potential to become a valuable option for managing ocular hypertension and open-angle glaucoma in eyes requiring cataract extraction, according to the study authors.
SpyGlass is enrolling patients in a phase 1/2 study with a larger patient pool and is working with the FDA to advance the program to commercial approval.
“The compelling clinical data ... suggest we are on track to bringing our innovative platform to patients,” Patrick Mooney, CEO of SpyGlass Pharma, said in a press release.
Reference:
- SpyGlass Pharma unveils compelling 1-year data of its innovative drug delivery platform implanted during routine cataract surgery in eyes with glaucoma. https://www.globenewswire.com/news-release/2024/04/02/2855881/0/en/SpyGlass-Pharma-Unveils-Compelling-1-Year-Data-of-Its-Innovative-Drug-Delivery-Platform-Implanted-During-Routine-Cataract-Surgery-in-Eyes-with-Glaucoma.html. Published April 2, 2024. Accessed April 17, 2024.
Collapse
Katz GJ, et al. Safety and efficacy of a long-duration sustained-release bimatoprost implant in eyes with ocular hypertension or mild to moderate glaucoma. Presented at: American Society of Cataract and Refractive Surgery meeting; April 5-8, 2024; Boston.
Read more about
Click Here to Manage Email Alerts